Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient

摘要

Solid pharmaceutical composition for oral administration having a sustained-release matrix, containing tilidine mesylate as an active ingredient. The content of tilidine mesylate ranges from 50-500mg of tilidine-HCl. The sustained-release matrix contains retardation agents hydrophilic and or hydrophobic polymers, and or fatty acids, glycerol esters of fatty acids, minerals and vegetable oils, waxes and or polyalkylene glycols.